Workflow
Pulmonx(LUNG)
icon
Search documents
Pulmonx Corporation (LUNG) Reports Q3 Loss, Misses Revenue Estimates
ZACKS· 2024-10-30 23:25
Pulmonx Corporation (LUNG) came out with a quarterly loss of $0.36 per share versus the Zacks Consensus Estimate of a loss of $0.43. This compares to loss of $0.39 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 16.28%. A quarter ago, it was expected that this company would post a loss of $0.41 per share when it actually produced a loss of $0.39, delivering a surprise of 4.88%. Over the last four quarters, the company has sur ...
Pulmonx Announces Presentation of Clinical Data from the AeriSeal® CONVERT Trial and 5-Year Follow-up Data from the LIBERATE Study at the European Respiratory Society Congress 2024
GlobeNewswire News Room· 2024-09-09 20:05
Core Insights - Pulmonx Corporation presented clinical data demonstrating the safety and effectiveness of the AeriSeal® System, with 77.6% of patients converting from collateral ventilation positive (CV+) to collateral ventilation negative (CV-) [1][3] - The 5-year follow-up data from the LIBERATE study showed that patients treated with Zephyr® Valves experienced durable improvements in lung function and quality of life [1][5] AeriSeal CONVERT Trial - The CONVERT trial included 101 patients with severe emphysema and collateral ventilation, showing that 77.6% successfully converted to CV- after treatment with the AeriSeal System [3][8] - Post-conversion, patients treated with Zephyr Valves exhibited an improvement in lung function of 80 mL or 10.2% as measured by Forced Expiratory Volume in 1 second (FEV1) [3] - Quality of life improved by 6.3 points on the St. George's Respiratory Questionnaire, and a mean treated lobe volume reduction (TLVR) of over one liter was observed at 45 days [3] LIBERATE Study 5-Year Follow-Up - The 5-year follow-up data indicated annual improvements in FEV1 ranging from 109 mL in Year 1 to 79 mL in Year 5, demonstrating the long-term benefits of Zephyr Valves [5][6] - The study reported a 38% mortality rate over the 5-year period, which is lower than the 49% mortality in historical medically managed control patients [6] Future Developments - Pulmonx is advancing the CONVERT II trial, expected to enroll approximately 200 patients, to further evaluate the AeriSeal System's effectiveness in limiting collateral ventilation [4][10] - The AeriSeal System has received a "Breakthrough Device" designation from the FDA, although it is not yet approved for commercial sale in the U.S. [9] Zephyr Valves Overview - Zephyr Valves are a minimally invasive treatment option for severe COPD/emphysema, designed to improve lung function and quality of life by blocking off diseased lung portions [11][12] - The valves are included in global treatment guidelines and have been used in over 40,000 patients worldwide [11][13]
AMGEN PRESENTS NEW DATA FOR FIRST-IN-CLASS IMDELLTRA™ (TARLATAMAB-DLLE) IN SMALL CELL LUNG CANCER AT WCLC 2024
Prnewswire· 2024-09-09 13:00
DeLLphi-303 Study Results Show Potential for IMDELLTRA in Combination with a PD-L1 Inhibitor as First-Line Maintenance Therapy in ES-SCLC DeLLphi-301 Long-Term Follow-up Data Demonstrate Sustained Safety and Efficacy for IMDELLTRA THOUSAND OAKS, Calif., Sept. 9, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the presentation of new data showcasing IMDELLTRATM (tarlatamab-dlle), a first-in-class delta-like ligand 3 (DLL3)-targeting Bispecific T-cell Engager (BiTE®) molecule, at the 2024 World Confe ...
Pulmonx to Participate in the Lake Street 8th Annual Best Ideas Growth Conference
GlobeNewswire News Room· 2024-08-29 20:05
REDWOOD CITY, Calif., Aug. 29, 2024 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) ("Pulmonx") a global leader in minimally invasive treatments for severe lung disease, today announced the company will be participating in investor meetings at the Lake Street 8th Annual Best Ideas Growth Conference in New York on Thursday, September 14, 2024. About Pulmonx Corporation Pulmonx Corporation (Nasdaq: LUNG) is a global leader in minimally invasive treatments for chronic obstructive pulmonary disease (COPD ...
Pulmonx to Present at the 2024 Wells Fargo Healthcare Conference
GlobeNewswire News Room· 2024-08-22 20:05
Company Overview - Pulmonx Corporation is a global leader in minimally invasive treatments for chronic obstructive pulmonary disease (COPD) [2] - The company's key products include the Zephyr® Endobronchial Valve, Chartis® Pulmonary Assessment System, and StratX® Lung Analysis Platform, which are designed to assess and treat severe emphysema/COPD patients [2] - The Zephyr Valve has received FDA pre-market approval and is commercially available in over 25 countries, widely recognized as a standard of care treatment option for severe emphysema [2] Upcoming Event - Pulmonx will participate in a fireside chat at the 2024 Wells Fargo Healthcare Conference in Boston on September 5, 2024, at 1:30 PM PT / 4:30 PM ET [1] - A live and archived webcast of the presentation will be available on the "Investors" section of the Pulmonx website [1]
Pulmonx Corporation (LUNG) Reports Q2 Loss, Tops Revenue Estimates
ZACKS· 2024-07-31 22:51
Pulmonx Corporation (LUNG) came out with a quarterly loss of $0.39 per share versus the Zacks Consensus Estimate of a loss of $0.41. This compares to loss of $0.43 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 4.88%. A quarter ago, it was expected that this company would post a loss of $0.43 per share when it actually produced a loss of $0.36, delivering a surprise of 16.28%. Over the last four quarters, the company has sur ...
Pulmonx Reports Second Quarter 2024 Financial Results
GlobeNewswire News Room· 2024-07-31 20:05
REDWOOD CITY, Calif., July 31, 2024 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) ("Pulmonx" or the "Company"), a global leader in minimally invasive treatments for lung disease, today reported financial results for the second quarter of 2024 ended June 30, 2024. Recent Highlights Achieved record worldwide revenue of $20.8 million in the second quarter of 2024, a 21% increase over the same period last year and an increase of 21% on a constant currency basis Delivered $13.9 million in U.S. revenue i ...
Pulmonx to Present at the Canaccord Genuity 44th Annual Growth Conference
GlobeNewswire News Room· 2024-07-29 20:05
Company Overview - Pulmonx Corporation is a global leader in minimally invasive treatments for chronic obstructive pulmonary disease (COPD) [2] - The company's key products include the Zephyr® Endobronchial Valve, Chartis® Pulmonary Assessment System, and StratX® Lung Analysis Platform, which are designed to assess and treat severe emphysema/COPD patients [2] - The Zephyr Valve has received FDA pre-market approval and is commercially available in over 25 countries, recognized as a standard of care treatment option for severe emphysema [2] Product and Market - The Zephyr Valve is designated as a "breakthrough device" by the FDA, highlighting its innovative nature and potential impact on patient care [2] - The Zephyr Valve is included in global treatment guidelines, indicating its widespread acceptance and adoption in the medical community [2] Investor Relations - Pulmonx Corporation will present at the Canaccord Genuity 44th Annual Growth Conference in Boston on August 13, 2024, at 5:00 AM PT / 8:00 AM ET [4] - A live and archived webcast of the presentation will be available on the "Investors" section of the Pulmonx website [1]
Pulmonx: Low Bar For Q2 Earnings
Seeking Alpha· 2024-07-21 13:00
Core Insights - Pulmonx's existing strategy is gaining traction, with Q1 revenues of $18.9 million reflecting a 30% year-over-year growth [3][15] - The company is not expected to make significant strategic changes in the near term, focusing instead on refining its current approach [6][30] - Despite positive revenue growth, Pulmonx's operating expenses significantly exceed revenues, leading to a projected breakeven point not expected until 2026 at the earliest [16][42] Financial Performance - Pulmonx reported Q1 revenues of $18.9 million, a 30% increase compared to the previous year [3][15] - Total operating expenses for Q1 were $28.6 million, resulting in a net loss of $13.7 million, an improvement from a loss of $15.9 million in the same quarter last year [7][16] - The company has a market capitalization of $307 million and an enterprise value of $228 million, with significant stock-based compensation impacting financials [12][20] Strategic Focus - The company aims to enhance physician awareness and best practices while continuing to attract large users of its Zephyr Valve [2][25] - There is a focus on maintaining existing strategies rather than pursuing mergers and acquisitions, despite the potential for a large total addressable market [30][40] - The CEO has indicated that while the strategy may need fine-tuning, no major shifts are anticipated in the immediate future [6][28] Future Outlook - Analysts forecast conservative revenue growth, with expectations of only high teens growth rates for upcoming quarters [21][36] - The company is positioned for a potential 'beat-and-raise' quarter due to strong sales momentum against conservative estimates [36][47] - Concerns remain regarding the company's ability to sustain operations until reaching breakeven, with estimates suggesting a need for approximately $160 million in operating losses before achieving this milestone [45][46]
Pulmonx to Report Second Quarter 2024 Financial Results on July 31, 2024
GlobeNewswire News Room· 2024-07-10 20:05
Core Insights - Pulmonx Corporation, a leader in minimally invasive treatments for lung disease, will release its financial results for Q2 2024 on July 31, 2024, after market close [1] - A conference call to discuss these results will be held at 1:30 p.m. PT / 4:30 p.m. ET on the same day [1] Company Overview - Pulmonx Corporation specializes in treatments for chronic obstructive pulmonary disease (COPD) and offers products such as the Zephyr® Endobronchial Valve, Chartis® Pulmonary Assessment System, and StratX® Lung Analysis Platform [3] - The Zephyr Valve has received FDA pre-market approval as a "breakthrough device" and is available in over 25 countries, recognized as a standard treatment option for severe emphysema [3] - The company's products aim to improve breathing, activity levels, and quality of life for patients suffering from severe emphysema/COPD [3]